Polynucleotides
Polynucleotides for dry or chapped lips: what does the evidence show?
A small study has examined polynucleotide injections for dry, rough lips, but the early findings do not prove that injections are better than appropriate lip care or treatment of an underlying cause.
Dry lips are a symptom, not a diagnosis
Lips may feel dry, rough or cracked because of weather, repeated licking, irritating products, dehydration or an inflammatory skin condition. A persistent sore, bleeding area, colour change or recurrent swelling needs assessment rather than being treated automatically as a cosmetic skin-quality concern. An injection should not delay investigation of an unexplained lesion.
The first step is therefore to understand the pattern and likely cause. Simple measures such as avoiding triggers and using a suitable protective lip product may be enough for some people. If there is active inflammation, infection, a cold sore or broken skin, elective injection may need to be postponed while the problem is assessed and managed.
What did the 2025 study examine?
A prospective multicentre study enrolled 30 Korean adults with visibly dry and chapped lips. Participants received one specific polynucleotide product in the lip vermilion at three appointments, each three weeks apart. Twenty-seven completed the nine-week study, and photographs were graded for lip wrinkles and roughness before treatment and during follow-up.
The investigators reported improvement from baseline in both grading scales at each follow-up. However, there was no untreated, placebo or standard-lip-care comparison group. Without a comparator, the study cannot show how much change resulted from the injections rather than repeated observation, seasonal change, additional lip care or the participants' expectations.
Why the result is preliminary
The sample was small, 29 of the 30 participants were women and every participant was Korean. Follow-up ended only three weeks after the third session, so the study does not establish how long any improvement lasted. The manufacturer supported the research, and the findings apply to the studied product and protocol rather than every injectable labelled polynucleotide.
A 2025 systematic review of polynucleotides in aesthetic medicine found only nine eligible studies involving 219 people across several concerns and treatment areas. It described promising changes in wrinkles, texture and elasticity, but judged the evidence low or moderate quality because methods, products and outcome measures varied. More research is still needed.
This is not the same as lip filler
Treatment for dryness or surface quality has a different goal from adding lip volume, changing the border or correcting structural asymmetry. Polynucleotide injection should not be presented as a predictable way to enlarge the lips. Any early fullness may partly reflect temporary swelling rather than an intended or lasting change in shape.
Equally, a course of injections is not automatically necessary because one study used three sessions. The number, interval and amount should follow the exact product information and an individual assessment. A protocol tested in one population cannot be assumed to be the best choice for every person, and more treatment does not guarantee more benefit.
Downtime and adverse effects matter
In the study, all participants had swelling 30 minutes after injection; pain and redness were also common, although reactions were mainly described as mild and temporary. Bruising, tenderness and small injection marks can be noticeable around the mouth, so treatment should not be scheduled immediately before an important event.
Less common complications can include infection, persistent inflammation, lumps or an allergic reaction. Increasing pain, heat, spreading redness, discharge, fever, unusual skin colour or worsening swelling needs prompt clinical advice. Difficulty breathing or features of a severe allergic reaction require urgent medical help. No lip injection should be described as risk-free.
Suitability begins with consultation
Consultation should cover the duration and triggers of dryness, current lip products, allergies, medicines, previous cold sores or reactions, other planned facial or dental procedures, pregnancy or breastfeeding, and the result the person hopes to achieve. Active disease or a concern outside the practitioner's competence may require medical assessment or referral instead of treatment.
The General Medical Council requires clear discussion of expected benefits, limitations, risks, alternatives and follow-up. For dry or chapped lips, that means comparing a modest and uncertain injectable benefit with appropriate non-invasive care and the option of no procedure. Treatment should proceed only when the goal is realistic and the individual balance is acceptable.